Last checked at 24 Jun 2014 09:23
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
ValiRx Share News (VAL)
VAL Share
Price
VAL Share
News
VAL Share
Chat
VAL Share
Trades14
VAL
Live RNS
VAL Share
Charts
VAL Level 2
Console
VAL Live
Share Price
VAL Broker
Ratings
VAL Directors
Deals
VAL Financial
Diary
VAL
Fundamentals
VAL Short
Positions
VAL
Media
ValiRx Information
Share Price Information for ValiRx (VAL)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
2.70
Bid:
2.60
Ask:
2.80
Change:
0.00 (0.00%)
Spread:
0.20 (7.692%)
Open:
2.70
High:
2.70
Low:
2.70
Prev. Close:
2.70
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Small caps round-up: Nyota Minerals, Mariana Resources, Bluestar...
Thu, 17th Jun 2010 08:14
Miner Nyota Minerals said drilling at its flagship Tulu Kapi gold project in Ethiopia has confirmed the presence of a new mineralized structure beneath the inferred resource of 1.38m ounces of gold.Also in gold mining, Mariana Resources said it made an encouraging intersection of gold north of the Belleza prospect in Chile.Chinese digital video surveillance firm BlueStar SecuTech has won a new contract with the Tangshan Public Security Bureau worth about RMB 9 million (£0.9 million). The contract is to provide networked surveillance services and solutions at approximately 300 Police Stations and 15 Police Security Bureaus in Tangshan City. This is BlueStar's first networking project with a municipal Public Security Bureau. Once the project has been successfully completed, BlueStar management believes it can be replicated in other cities across China according to the requirement by The Ministry of Public Security of China.Drug delivery and device technologies firm Consort Medical saw pre-tax profit fall 13% to £10.5m on revenue that fell to £118.6m from £120.3m before.The group said the results were due to the group facing destocking across its markets during the year, a material price reduction in one of Bespak's key contracts and a weak hospital market in the US for King Systems. Final dividend was maintained at 12.1p per share.Marketing services company Work Group said Rose Colledge will be appointed group chief executive with effect from June 21st, while finance director Michael Warren has decided to step down with effect from July 31st. "We have maintained our broad spread of clients and only 10 per cent of our income is derived from public sector organisations. Consequently we see no reason why expectations for the current year will not be met," said the group.Biopharmaceutical tiddler Valirx said it has now completed the first year of a two year Eurostars grant programme in which all developmental milestones have been met.
More News
10 Jun 2014 10:00
ValiRx Submits Application For VAL201 Cancer Study
LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.
Read more10 Jun 2014 09:45
Tuesday broker round-up UPDATE
ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu
Read more15 May 2014 13:31
ValiRx Sees Progress On Cancer Drug Development From Joint Venture
LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre
Read more1 May 2014 10:15
ValiRx Granted Patent For Cancer Screening Biomarker In Japan
LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i
Read more8 Apr 2014 11:05
ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development
LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6
Read more1 Apr 2014 09:22
ValiRx Anti-Cancer Compound To Undergo Further Study
LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea
Read more19 Mar 2014 12:10
ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme
LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2
Read more20 Feb 2014 11:10
ValiRx Biomarket Receives European Patent Approval
LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in
Read more31 Jan 2014 13:03
ValiRx Sells Shares In VolitionRx For USD601,578
LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c
Read more